Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial exchanges : Nyse save search
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
Published: 2024-04-23 (Crawled : 11:00) - globenewswire.com
TOVX | News | $0.3769 -8.3% -1.83% 1.2M
|
Manufacturing
|
| O: 0.73%
H: 0.0%
C: 0.0%
vcn-01 positive topline trial
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
| Email alert
Add to watchlist
EW | $87.75 0.91% 0.0% 2.7M
|
Health Technology
| Email alert
Add to watchlist
treatment for women smart trial platform
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.97 6.2% 2.21% 400K
|
Health Technology
|
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta trial therapeutics
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
LUXH FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages LuxUrban Hotels, Inc. Investors to Secure Counsel Before Important April 12 Deadline in Securities Class Action - LUXH
Published: 2024-04-02 (Crawled : 00:00) - prnewswire.com
LUXH | $0.8797 -5.64% -5.98% 150K
|
|
| O: -0.71%
H: 2.86%
C: -2.86%
BCDRF | $4.978 -8.71% 100
|
Finance
|
| O: 3.9%
H: 4.33%
C: 4.33%
SHLS | $8.45 0.24% 0.24% 3.2M
|
|
| O: 0.19%
H: 2.0%
C: 0.84%
SAN | $4.99 2.68% -0.2% 11M
|
Finance
|
| O: 1.04%
H: 1.23%
C: 0.82%
deadline trial
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | News | $306.16 2.76% 2.68% 860K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-03-25 (Crawled : 16:00) - prnewswire.com
TMO | News | $574.59 4.78% -1.12% 2.5M
|
Health Technology
|
| O: 0.02%
H: 0.31%
C: -1.65%
INFY | $17.16 -0.81% 0.41% 8.3M
|
Technology Services
|
| O: 0.4%
H: 0.0%
C: -0.9%
CTLT | $56.03 -0.04% 0.0% 1.5M
|
Health Technology
|
| O: 0.54%
H: 0.82%
C: 0.55%
ICLR | News | $306.16 2.76% 2.68% 860K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.68%
report reach trial market
EVVTY DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EVVTY
Published: 2024-03-24 (Crawled : 16:20) - prnewswire.com
BCDRF | $4.978 -8.71% 100
|
Finance
| Email alert
Add to watchlist
SAN | $4.99 2.68% -0.2% 11M
|
Finance
| Email alert
Add to watchlist
deadline trial
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
ROSEN, LEADING TRIAL ATTORNEYS, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IRBT
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
BTAFF | $30.26 44.6% 2.1K
|
Consumer Non-Durables
|
| O: -3.87%
H: 0.0%
C: -1.14%
BTI | $29.56 0.51% 0.07% 4.2M
|
Consumer Non-Durables
|
| O: -2.13%
H: 0.26%
C: -0.56%
IRBT | $6.88 2.08% 2.03% 1.4M
|
Consumer Durables
|
| O: 0.81%
H: 2.88%
C: -3.11%
AMZN S | $179.59 1.33% 1.31% 36M
|
Retail Trade
|
| O: 1.03%
H: 0.79%
C: -1.02%
corporation deadline trial
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
FTFT DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Future FinTech Group Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - FTFT
Published: 2024-03-16 (Crawled : 00:20) - prnewswire.com
EAF | $1.57 -1.88% 0.0% 2M
|
Producer Manufacturing
| Email alert
Add to watchlist
BCDRF | $4.978 -8.71% 100
|
Finance
| Email alert
Add to watchlist
FTFT | $0.841 -0.73% -0.74% 21K
|
Consumer Non-Durables
| Email alert
Add to watchlist
SAN | $4.99 2.68% -0.2% 11M
|
Finance
| Email alert
Add to watchlist
first deadline group trial
Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and Clinical Trial Activity Reflect Growing Interest in the Market
Published: 2024-03-15 (Crawled : 15:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
partnership precision global trends growing trial market
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Palo Alto Networks, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PANW
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
XPOF | $12.59 -0.87% 0.0% 1.5M
|
|
| O: 0.59%
H: 2.21%
C: -1.89%
PANW | $293.565 4.22% 4.05% 4M
|
Electronic Technology
|
| O: 0.31%
H: 2.51%
C: 1.58%
IRBT | $6.88 2.08% 2.03% 1.4M
|
Consumer Durables
|
| O: -0.41%
H: 4.58%
C: -0.31%
deadline trial
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE | News A | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.